Adial CEO William Stilley Invited to Participate in Maxim Group’s Virtual Panel Series Conference: “Disruptors in the Mental Health Space”
16 September 2021 - 12:07AM
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW)
(“Adial” or the “Company”), a clinical-stage biopharmaceutical
company focused on developing therapies for the treatment and
prevention of addiction and related disorders, today announced that
William Stilley, Chief Executive Officer of Adial
Pharmaceuticals, has been invited to participate in Maxim
Group’s virtual panel series conference: "Disruptors in the Mental
Health Space," which will be taking place on Wednesday, September
22, 2021 from 9:00am-3:00pm ET.
The conference will consist of a series of
roundtable panel discussions that will include speakers from both
psychedelic, and non-psychedelic, focused companies. Leading and
moderating the panel discussions will be Maxim’s Biotechnology
Team, led by Dr. Jason McCarthy.
Mr. Stilley has accepted an invitation as a
speaker on the panel addressing addiction, which will begin at
9:00am ET. Registered attendees can view the panel via the
conference platform; individual and institutional investors can
sign up to register for the conference here.
For more information about the conference,
please contact Maxim at jthompson@maximgrp.com.
About Adial Pharmaceuticals,
Inc.
Adial Pharmaceuticals is a clinical-stage
biopharmaceutical company focused on the development of treatments
for addictions. The Company’s lead investigational new drug
product, AD04, is a genetically targeted, serotonin-3 receptor
antagonist, therapeutic agent for the treatment of Alcohol Use
Disorder (AUD) and is currently being investigated in the Company’s
landmark ONWARD™ pivotal Phase 3 clinical trial for the potential
treatment of AUD in subjects with certain target genotypes, which
are to be identified using the Company’s proprietary companion
diagnostic genetic test. A Phase 2b clinical trial of AD04 for the
treatment of AUD showed promising results in reducing frequency of
drinking, quantity of drinking and heavy drinking (all with
statistical significance), and no overt safety concerns (there were
no statistically significant serious adverse events reported). AD04
is also believed to have the potential to treat other addictive
disorders such as Opioid Use Disorder, gambling, and obesity. The
Company is also developing adenosine analogs for the treatment of
pain and other disorders. Additional information is available at
www.adialpharma.com.
Contact:Crescendo Communications,
LLC David
Waldman / Natalya
Rudman Tel:
212-671-1021 Email:
adil@crescendo-ir.com
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024